# Phase 4 Study of Dolutegravir (DTG) in Russian Federation

> **NCT03314064** · PHASE4 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 43 (actual)

## Conditions studied

- Infection, Human Immunodeficiency Virus
- HIV Infections

## Interventions

- **DRUG:** Dolutegravir 50 mg

## Key facts

- **NCT ID:** NCT03314064
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-08
- **Primary completion:** 2018-10-01
- **Final completion:** 2018-10-01
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2019-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03314064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03314064, "Phase 4 Study of Dolutegravir (DTG) in Russian Federation". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03314064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*